Trials / Conditions / Stage IV Hypopharyngeal Carcinoma AJCC v8

Stage IV Hypopharyngeal Carcinoma AJCC v8

15 registered clinical trials studyying Stage IV Hypopharyngeal Carcinoma AJCC v8 — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Nec NCT06868433	Emory University	Phase 1
Recruiting	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returni NCT06589804	National Cancer Institute (NCI)	Phase 3
Recruiting	Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058	Emory University	N/A
Recruiting	Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, NCT06636734	Emory University	Phase 2
Withdrawn	Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carbopl NCT06084845	ECOG-ACRIN Cancer Research Group	Phase 2
Active Not Recruiting	Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the NCT05721755	ECOG-ACRIN Cancer Research Group	Phase 3
Active Not Recruiting	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy NCT05063552	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196	National Cancer Institute (NCI)	Phase 2
Withdrawn	A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Canc NCT05512767	Mayo Clinic	N/A
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) NCT05172258	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcin NCT04862650	Marcelo Bonomi	Phase 2
Completed	Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With NCT04541355	Hyunseok Kang, MD	Phase 2
Terminated	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer NCT04162873	University of Utah	Phase 2
Recruiting	Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With NCT03010150	M.D. Anderson Cancer Center	—